Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Reboxetine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 13/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 12/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 1.00 |
| ▸ | MLNR | O43193 | 1/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 1/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | HRH1 | P35367 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Reboxetine SCHEMBL3185555 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3MLNRADRB2 | |
| Reboxetine SCHEMBL6737649 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3MLNRADRB2 | |
| Reboxetine SCHEMBL1694154 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3MLNRADRB2 | |
| Reboxetine SCHEMBL13631332 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3MLNRADRB2 | |
| Reboxetine SCHEMBL34533 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3MLNRADRB2 | |
| Reboxetine SCHEMBL5783865 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3MLNRADRB2 | |
| Esreboxetine SCHEMBL34534 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3MLNRADRB2 | |
| Reboxetine SCHEMBL3195078 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3MLNRADRB2 | |
| Reboxetine SCHEMBL3185550 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3MLNRADRB2 | |
| Reboxetine SCHEMBL29930185 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3MLNRADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 230 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291953-A1 | PHARMACEUTICAL SALTS OF REBOXETINE | PFIZER INC | 2009-11-26 | — | — | US | claimed |
| EP-1515959-B1 | PHARMACEUTICAL SALTS OF REBOXETINE | PFIZER ITALIA SRL (IT) | 2009-08-12 | — | — | EP | claimed |
| EP-1744754-A1 | MORPHOLINE COMPOUNDS | Pfizer Limited (GB) | 2007-01-24 | — | — | EP | claimed |
| EP-1745029-A1 | SUBSTITUTED MORPHOLINE COMPOUNDS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | Warner-Lambert Company LLC (US) | 2007-01-24 | — | — | EP | claimed |
| US-20070010517-A1 | Pharmaceutical salts of reboxetine | PFIZER ITALIA S.R.L. F/K/A PHARMACIA ITALIA S.P.A. (IT) | 2007-01-11 | — | — | US | claimed |
| WO-2005105763-A1 | SUBSTITUTED MORPHOLINE COMPOUNDS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | WARNER-LAMBERT COMPANY LLC (US) | 2005-11-10 | — | — | WO | claimed |
| WO-2005105100-A1 | MORPHOLINE COMPOUNDS | PFIZER LIMITED (GB) | 2005-11-10 | — | — | WO | claimed |
| US-20050250775-A1 | Novel compounds | FISH PAUL V | 2005-11-10 | — | — | US | claimed |
| US-20050245519-A1 | Substituted morpholine compounds for the treatment of central nervous system disorders | WARNER-LAMBERT COMPANY LLC | 2005-11-03 | — | — | US | claimed |
| EP-1515959-A1 | PHARMACEUTICAL SALTS OF REBOXETINE | Pharmacia Italia S.p.A. (IT) | 2005-03-23 | — | — | EP | claimed |
| WO-2004058353-A2 | THERAPEUTIC USE OF SELECTIVE NORADRENALINE REUPTAKE INHIBITORS | PARADIGM THERAPEUTICS LTD. (GB) | 2004-07-15 | — | — | WO | claimed |
| WO-2003106441-A1 | PHARMACEUTICAL SALTS OF REBOXETINE | PHARMACIA ITALIA S.P.A. (IT) | 2003-12-24 | — | — | WO | claimed |
| US-5391735-A | Process for the preparation of 3-substituted derivatives of 1-amino-2-hydroxy-propane | FARMITALIA CARLO ERBA S.P.A. (IT) | 1995-02-21 | — | — | US | claimed |
| EP-0216247-A2 | Use of alpha 2 adrenergic receptor antagonists for the production of pharmaceutical compositions for treating colonic spasm, irritable bowel syndrome and constipation and process for preparing such pharmaceutical compositions | MERCK & CO. INC. (US) | 1987-04-01 | — | — | EP | claimed |
| WO-2025106773-A1 | METHODS AND COMPOSITIONS FOR TREATING SLEEP APNEA WITH A COMBINATION OF A GLP-1 AGONIST AND A SECOND ACTIVE AGENT | APNIMED, INC. (DELAWARE) (US) | 2025-05-22 | — | — | WO | disclosed |
| US-20240139200-A1 | COMBINATION OF REBOXETINE AND A MUSCARINIC RECEPTOR ANTAGONIST (MRA) FOR USE IN TREATING SLEEP APNEA | APNIMED, INC. (DELAWARE) | 2024-05-02 | — | — | US | disclosed |
| EP-4355333-A1 | NOREPINEPHRINE REUPTAKE INHIBITORS FOR TREATING SLEEP APNEA | APNIMED, INC. (DELAWARE) (US) | 2024-04-24 | — | — | EP | disclosed |
| EP-0216247-A2 | Use of alpha 2 adrenergic receptor antagonists for the production of pharmaceutical compositions for treating colonic spasm, irritable bowel syndrome and constipation and process for preparing such pharmaceutical compositions | MERCK & CO. INC. (US) | 1987-04-01 | — | — | EP | disclosed |
| US-4271160-A | Substituted morpholine derivatives and pharmaceutical compositions | FARMITALIA CARLO ERBA S.P.A. (IT) | 1981-06-02 | — | — | US | disclosed |
| US-4229449-A | ANTIDEPRESSANTS | FARMITALIA CARLO ERBA, S.P.A. (IT) | 1980-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010517-A1 | Pharmaceutical salts of reboxetine | SLC6A2, SLC6A4, SLC6A3 | SLC6A2 1/4885SLC6A4 2/4885SLC6A3 3/4885 |
| US-20050250775-A1 | Novel compounds | OPRL1, UGT1A1, NPSR1 | SLC6A2 133/4885SLC6A4 114/4885SLC6A3 104/4885 |
| US-20050245519-A1 | Substituted morpholine compounds for the treatment of central nervous system disorders | CNR1, OPRM1, HCRTR1 | SLC6A2 124/4885SLC6A4 235/4885SLC6A3 93/4885 |
| US-20090291953-A1 | PHARMACEUTICAL SALTS OF REBOXETINE | SLC6A2, SLC6A4, SUCNR1 | SLC6A2 1/4885SLC6A4 2/4885SLC6A3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.